Irritable Bowel Syndrome Treatment Market To Reach $6.02 Billion By 2030

Irritable Bowel Syndrome Treatment Market Growth & Trends

The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient’s professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient’s professional and personal activities, and usually limits an individual’s potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

 Request a free sample copy or view report summary: Irritable Bowel Syndrome Treatment Market Report

Irritable Bowel Syndrome Treatment Market Report Highlights

• The IBS-C segment is expected to grow at a CAGR of 11.9% over the forecast period, owing to the increasing prevalence of this condition and the rising adoption of effective medications such as Linzess (linaclotide) and Amitiza (lubiprostone).

• The IBS-D segment dominated the market with the largest revenue share of 49.8% in 2024 attributed to a rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life.

• Linzess/Constella dominated the market and accounted for the largest revenue share of 37.3% in 2024 attributed to its effectiveness in managing constipation-predominant IBS (IBS-C).

• Hospital pharmacies led the market and accounted for the largest revenue share in 2024, which is attributed to their comprehensive infrastructure and integrated patient care systems.

• North America irritable bowel syndrome (IBS) treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to the high prevalence of IBS and the increasing awareness of its management options.

• The growth of Europe irritable bowel syndrome treatment market is driven by increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. Countries such as Germany and the UK are seeing increased patient engagement regarding IBS symptoms and available treatments.

Irritable Bowel Syndrome Treatment Market Segmentation

Grand View Research has segmented the global irritable bowel syndrome treatment market on the basis of on type, drug class, distribution channel, and region:

Irritable Bowel Syndrome Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• IBS-C

• IBS-D

Irritable Bowel Syndrome Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Xifaxan

• Linzess/Constella

• Viberzi

• Amitiza

• Others

Irritable Bowel Syndrome Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others

Irritable Bowel Syndrome Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

• Asia Pacific

  • China

  • Japan

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

List of Key Players in the Irritable Bowel Syndrome Treatment Market

• Ironwood Pharmaceuticals, Inc.

• Allergan

• Astellas Pharma, Inc.

• Takeda Pharmaceutical Company Limited

• AstraZeneca

• Sanofi S.A.

• Sebela Pharmaceuticals Inc.

• Bausch Health

• Synthetic Biologics, Inc.

• Ardelyx